|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 8280 WILLOW OAKS CORPORATE DRIVE |
Address2 | SUITE 500 |
City | FAIRFAX |
State | VA |
Zip Code | 22031 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 57737-12
|
||||||||
|
6. House ID# 352510000
|
TYPE OF REPORT | 8. Year | 2009 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Emily Wilson, Director of Government Relations |
Date | 01/20/2010 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
To protect access to medical isotopes used in cancer treatments such as brachytherapy and stereotactic radiosurgery.
Development of domestic medical isotope production, specifically the American Medical Isotope Production Act of 2009 (H.R. 3276).
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Energy - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Emily |
Wilson |
|
|
|
Dave |
Adler |
|
|
|
Richard |
Martin |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Support for the Access to Cancer Clinical Trials Act of 2009 (S. 488, H.R. 716) to provide access to clinical trials for cancer patients.
Support for health care reform provisions in the America's Healthy Future Act (H.R. 3200), the Patient Protection and Affordable Care Act (H.R. 3590), and the Affordable Health Choices Act (S. 1796) to reform health care through a combination of public and private approaches to cover medically necessary services; support review and development of national workforce strategy; support elimination of pre-existing condition limitations; support medical liability reform; support consumer protection from annual and lifetime insurance limits; provide funding for comparative effectiveness research; and support expanded access to and use of regular health assessments and preventive services, including early screening and detection.
Support a definition for meaningful use of health care technology that allows specialty physicians to benefit from incentive payments for the use of specialty-specific products.
Support for the development of domestic medical isotope production, specifically American Medical Isotope Production Act of 2009 (H.R. 3276).
Letter to FDA supporting regulation to ensure the validity of in vitro diagnostic tests.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Energy - Dept of, Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Emily |
Wilson |
|
|
|
Dave |
Adler |
|
|
|
Richard |
Martin |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Support for legislation to rebase the Medicare physician payment formula to stabilize physician payments, including support for the Medicare Physician Fairness Act of 2009 (S. 1776) and the Medicare Physician Payment Reform Act (H.R. 3961).
Advocacy to stop the 19 percent cut for radiation oncology services proposed by CMS in the 2010 proposed physician fee schedule.
Support for legislation to insure patient safety and preserve the integrity of the Medicare program by ending abuses of the physician self-referral law for radiation therapy services.
Comprehensive Cancer Care Improvement Act of 2009 (H.R. 1844) to expand cancer care planning, comprehensive symptom management and to authorize demonstrations for hospice and palliative care for cancer patients.
Legislation to support structural changes that lead to delivering high-quality care for patients while increasing efficiencies and promoting Medicare sustainability; oppose radiation oncology benefit managers.
Support for H.R. 3095 to provide Medicare coverage for cancer patients.
Oppose Gregg amendment to health care reform requiring public reporting of quality data.
Letter to CMS regarding provider enrollment issues.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Emily |
Wilson |
|
|
|
Dave |
Adler |
|
|
|
Richard |
Martin |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
Review of brachytherapy treatments at Philadelphia VA and testimony to promote brachytherapy as a safe cancer treatment option.
Support for the Veterans' Health and Radiation Safety Act (H.R. 4062) to ensure oversight of radiation oncology procedures are carried out in an effective and efficient manner while maintaining patient safety.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Nuclear Regulatory Commission (NRC), Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Emily |
Wilson |
|
|
|
Dave |
Adler |
|
|
|
Richard |
Martin |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Support for increasing cancer research funding, including support for the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2010 (H.R. 3293).
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Emily |
Wilson |
|
|
|
Dave |
Adler |
|
|
|
Shandi |
Hill |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |